Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $21,700.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00. Following the completion of the sale, the president now owns 2,905,138 shares of the company’s stock, valued at approximately $31,520,747.30. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.

Gyre Therapeutics Stock Performance

GYRE opened at $11.19 on Friday. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $26.37. The company has a 50-day moving average price of $11.17 and a 200 day moving average price of $12.59.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently made changes to their positions in GYRE. FMR LLC purchased a new position in Gyre Therapeutics in the 3rd quarter worth approximately $47,000. Barclays PLC boosted its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the period. Rhumbline Advisers acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at approximately $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics during the 2nd quarter worth about $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.